Abstract: The present application is directed to agents that bind an epitope specific to a ?3 ?? TCR. Such agents can be, but are not limited to, an antibody or fragment thereof. Also described herein are methods for using the agents, e.g., to expand or selectively expand ?3 ?? T cells. Also described herein are methods of using expanded ?3 ?? T cells for treatment of a subject in need thereof.
Type:
Grant
Filed:
November 15, 2018
Date of Patent:
February 11, 2025
Inventors:
Aya Jakobovits, Daulet Kadyl Satpayev, Orit Foord, Yifeng Frank Jing, Hui Shao, Jason Michael Romero, Mary Michael Brody, Matthew Ian Hoopes
Abstract: The technology described herein is directed to CAR polypeptides and systems comprising repressible proteases. In combination with a specific protease inhibitor, the activity of said CAR polypeptides and systems and cells comprising them can be modulated. Also described herein are methods of using said CAR polypeptides and systems, for example to treat various diseases and disorders.
Type:
Grant
Filed:
June 9, 2021
Date of Patent:
January 21, 2025
Assignee:
TRUSTEES OF BOSTON UNIVERSITY
Inventors:
John Ngo, Wilson Wong, Meng Lai Nicole Wong, Huishan Li, Elliot P. Tague
Abstract: This invention relates to humanised versions of the murine anti-IL17BR antibody D9.2 which comprise mutations of certain residues within the heavy chain and/or light chain variable domains that display improved expression without deleterious effects on specificity or affinity. The humanised antibodies may comprise a heavy chain variable (VH) domain which comprises a VHCDR1 of SEQ ID NO: 1, a VHCDR2 of SEQ ID NO: 2, and a VHCDR3 of SEQ ID NO: 3, for example, a VH domain of SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11. The humanised antibodies may comprise a light chain variable (VL) domain which comprises a VLCDR1 of SEQ ID NO: 4, a VLCDR2 of SEQ ID NO: 5, and a VLCDR3 of SEQ ID NO: 6, for example a VL domain of SEQ ID NO: 13. Antibodies, pharmaceutical compositions and methods of use, for example in the treatment of cancer are provided.
Abstract: Anti-CD19 heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B cell disorders that are characterized by the expression of CD19.
Type:
Grant
Filed:
July 19, 2019
Date of Patent:
January 21, 2025
Assignee:
TeneoTwo, Inc.
Inventors:
Shelley Force Aldred, Wim van Schooten, Katherine Harris, Udaya Rangaswamy, Nathan Trinklein
Abstract: The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) Venetoclax; methods for preparing pharmaceutical combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity.
Type:
Grant
Filed:
June 13, 2019
Date of Patent:
January 14, 2025
Assignee:
Berlin-Chemie AG
Inventors:
Giuseppe Merlino, Mario Bigioni, Monica Binaschi, Andrea Pellacani
Abstract: The present invention provides chimeric antigen receptors, cells expressing same and methods of using same for treatment various disorders such as cancer.
Abstract: The present disclosure provides chimeric antigen receptors that bind to Axl and Ror2, and conditionally active chimeric antigen receptors (CARs) that recognize Axl and Ror2. Furthermore, provided herein are nucleic acids encoding these CARs and methods of making and using the CARs, including methods of treating cancer, especially cancers that express Axl and/or Ror2, such as renal cell carcinoma. The present disclosure provides cells genetically modified to produce the CARs.
Type:
Grant
Filed:
January 17, 2018
Date of Patent:
January 7, 2025
Assignees:
Exuma Biotech Corp., BioAtla. Inc.
Inventors:
Gregory Ian Frost, James Joseph Onuffer, Jr., Jay M. Short, Gerhard Frey, Hwai Wen Chang
Abstract: The present invention provides a regulatory T (Treg) cell expressing an antigen chimeric receptor (CAR) comprising a) at least one antigen binding domain, b) a transmembrane domain, and c) a cytoplasmic signaling domain comprising at least one primary cytoplasmic signaling domain and at least the co-stimulatory signaling domain of CD137, wherein said antigen binding domain specifically binds an antigen that is expressed on the surface of a target cell or a tag of a tagged polypeptide that binds to an antigen expressed on the surface of a target cell or a soluble antigen. Compositions comprising said Treg cells, and methods of enrichment and analysis of activated Tregs that express said CAR are also disclosed.
Type:
Grant
Filed:
January 17, 2019
Date of Patent:
December 31, 2024
Assignees:
Miltenyi Biotec B.V. & Co. KG, Charité—Universitätsmedizin Berlin
Inventors:
Anna Nowak, Dominik Lock, Andrew Kaiser, Alexander Scheffold
Abstract: Pharmaceutical compositions of anti-TSLP-R antibodies, and uses thereof, are provided herein. The pharmaceutical compositions can comprise for example, an anti-TSLP-R antibody, or antigen-binding fragment thereof, a pharmaceutically acceptable buffer, an excipient, and a surfactant, or other compositions as provided for herein.
Type:
Grant
Filed:
November 7, 2023
Date of Patent:
November 26, 2024
Assignee:
UPSTREAM BIO, INC.
Inventors:
Parika Petaipimol, Robert Patrick Gearing, Bingquan Wang, Geng Li, Jeremy Guo
Abstract: The present invention provides T-cells modified to express at least two chimeric antigen receptors, wherein one of the CARs binds specifically to an antigen selected from CD138, HER2 and CD24 and another CAR binds specifically a different antigen selected from CD 138, HER2 and CD24. Further, the invention provides pharmaceutical compositions comprising these CAR T-cells and their use in treatment of cancer, in particular, ovarian cancer, DNA constructs encoding said CARs and methods for preparation of T-cells expressing said CARs.
Type:
Grant
Filed:
December 4, 2018
Date of Patent:
November 12, 2024
Assignees:
THE MEDICAL RESEARCH INFRASTRUCTURE AND HEAL SERVICED FUND OF THE TEL AVIV MEDECAL CENTER, YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventors:
Zelig Eshhar, Tova Waks, Anat Globerson Levin, Naamit Deshet-Unger, Moran Rawet Slobodkin, Dan Grisaru, Ben Zion Katz, Ido Laskov
Abstract: The present application relates to an antigen-binding polypeptide that specifically binds to B7H3, comprising at least one complementarity-determining region (CDR) of an antibody heavy chain variable region (VH), wherein the VH comprises an amino acid sequence set forth in SEQ ID NO: 25. The present application further relates to a chimeric antigen receptor comprising the antigen-binding polypeptide and a universal CAR-T cell comprising the chimeric antigen receptor. The CAR-T cell recognizes a surface antigen of a tumor cell and knocks out TCR and HLA-A genes expressed by the cell at the same time, so that the immune rejection caused by an allogeneic CAR-T therapy is reduced, the survival time of the cell is prolonged, and the anti-tumor effect is improved.
Abstract: The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.
Abstract: This disclosure relates to dimeric immunotherapeutics that comprise two IgGs that are crosslinked with a disulfide bond. The two IgGs may be chimeras of two different heavy chains, in which one heavy chain includes a cysteine mutation that forms the disulfide bond, and the other heavy chain lacks the cysteine mutation. The presence of a cysteine mutation in only one of the heavy chains of an IgG avoids two disulfide bonds between the two IgGs, which increases the accessible orientations between the two crosslinked IgGs, and also avoids the formation of trimers and higher-order oligomers.
Abstract: The invention provides methods to inhibit or treat brain cancers by locally inhibiting expression or activity of growth factors or growth factor receptors.
Type:
Grant
Filed:
July 13, 2020
Date of Patent:
October 22, 2024
Assignees:
Cornell University, Memorial Sloan-Kettering Cancer Center
Inventors:
Ronald G. Crystal, Stephen M. Kaminsky, Martin J. Hicks, Viviane Tabar
Abstract: The present application discloses an antibody or antigen-binding fragment thereof that binds specifically to a BAG2 polypeptide or fragment thereof, and a method of treating cancer thereof.
Abstract: The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (CDR). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point. The present invention further provides antibodies with a modified isoelectric point, pharmaceutical compositions comprising the antibodies as an active ingredient, and methods for producing the antibodies and compositions.
Abstract: Disclosed herein are chimeric antigen receptors (CARs) that target MUC1*. In some embodiments, the CARs have been optimized to reduce T cell exhaustion.
Abstract: This disclosure relates to dimeric immunotherapeutics that comprise two IgGs that are crosslinked with a disulfide bond. The two IgGs may be chimeras of two different heavy chains, in which one heavy chain includes a cysteine mutation that forms the disulfide bond, and the other heavy chain lacks the cysteine mutation. The presence of a cysteine mutation in only one of the heavy chains of an IgG avoids two disulfide bonds between the two IgGs, which increases the accessible orientations between the two crosslinked IgGs, and also avoids the formation of trimers and higher-order oligomers.